Equine MEED genomics study points to a new mutation target: full analysis
A new equine genomics study is pushing a rare, poorly understood disease into more mechanistic territory. In Animals, researchers reported whole-genome sequencing of a horse with multisystemic eosinophilic epitheliotropic disease, or MEED, and compared that genome with 40 controls to look for rare, potentially damaging variants. The study abstract says the team generated high-depth sequencing at about 40× coverage and identified more than 6.3 million variants, with moderate- and high-impact changes enriched among low-frequency variants. (pubmed.ncbi.nlm.nih.gov)
That matters because MEED has historically been defined by clinicopathology rather than molecular biology. The disease is rare in horses and other equids, and published literature still consists largely of case reports, case series, and reviews. Clinical signs can be broad and nonspecific, including weight loss, diarrhea, dermatitis, respiratory signs, lymphadenopathy, and eosinophilia, depending on which organ systems are involved. Diagnosis can be challenging, and prognosis is generally poor. (academic.oup.com)
Background literature shows how little certainty clinicians have had to work with. A recent Journal of Veterinary Internal Medicine donkey case review noted that MEED in equids remains rare and variably expressed, while Merck Veterinary Manual states that the pathophysiology of equine inflammatory bowel diseases, including MEED, is not well understood. Merck also notes that Standardbreds appear predisposed to MEED, suggesting a possible genetic contribution, but that idea has remained largely untested in published clinical literature. (academic.oup.com)
Additional detail from a 2026 Texas Tech University Phi Zeta abstract appears to reflect the same research program and gives a clearer look at the candidate finding. In that abstract, the team said it aligned paired-end whole-genome reads to EquCab3.0, called and filtered germline variants, annotated them with a custom SnpEff database, and prioritized variants in candidate genes before modeling protein-altering hits in AlphaFold 3. Their highest-priority candidate was a heterozygous stop-gained variant in USP25, which would be expected to truncate the encoded protein. The authors described USP25 as an important regulator of inflammation and innate immune signaling and suggested the variant could contribute to the immune dysregulation seen in MEED. That interpretation is still preliminary, but it offers a concrete molecular lead in a disease that has lacked one. (depts.ttu.edu)
Independent expert reaction specifically to this paper was not readily available in the sources reviewed, which is not surprising for a niche equine genomics report. Still, the broader veterinary literature supports the significance of the question. MEED is considered a grave-prognosis condition, and current diagnosis still relies heavily on biopsy and histopathology, with rectal mucosal biopsy helping in only about half of GE and MEED cases, according to Merck. In that context, even an early-stage candidate mutation is notable, especially if it helps explain why some horses develop severe multisystem eosinophilic inflammation. (merckvetmanual.com)
Why it matters: For veterinary professionals, this is best viewed as a signal-generating study, not a practice-changing one. A single affected horse and a control comparison can identify plausible targets, but it can’t establish causality on its own. Even so, the work is useful because it starts building the genomic infrastructure MEED has lacked: a variant catalog, a candidate-gene shortlist, and a hypothesis linking disease phenotype to immune-pathway disruption. If validated, that could eventually influence how referral clinicians think about diagnosis, prognosis, breeding risk, and research enrollment in horses with unexplained eosinophilic multisystem disease. (depts.ttu.edu)
There’s also a translational angle. The same Texas Tech group has separately reported establishing primary equine lymph node endothelial cells from a 3-year-old horse with MEED, describing that system as a potential in vitro model for drug-response and pathway studies. Taken together, the sequencing work and cell-model development suggest a broader effort to move from descriptive pathology toward functional investigation and, eventually, target-based therapy research. (agris.fao.org)
What to watch: The next key step is replication. Veterinary professionals should watch for the full paper’s complete methods and variant list, plus any follow-up screening of additional MEED cases, breed-level analyses, or functional work testing whether USP25 disruption consistently tracks with disease biology in horses. (depts.ttu.edu)